APA (7th ed.) Citation

Zhou, X., Yang, X., Grinshpun, B., Taylor, A., Strong, L., Dasari, A., . . . Chien, C. (2025). Population Pharmacokinetics of Fruquintinib, a Selective Oral Inhibitor of VEGFR ‐1, ‐2, and ‐3, in Patients with Refractory Metastatic Colorectal Cancer. Journal of clinical pharmacology, 65(7), 873-884. https://doi.org/10.1002/jcph.70001

Chicago Style (17th ed.) Citation

Zhou, Xiaofei, et al. "Population Pharmacokinetics of Fruquintinib, a Selective Oral Inhibitor of VEGFR ‐1, ‐2, and ‐3, in Patients with Refractory Metastatic Colorectal Cancer." Journal of Clinical Pharmacology 65, no. 7 (2025): 873-884. https://doi.org/10.1002/jcph.70001.

MLA (9th ed.) Citation

Zhou, Xiaofei, et al. "Population Pharmacokinetics of Fruquintinib, a Selective Oral Inhibitor of VEGFR ‐1, ‐2, and ‐3, in Patients with Refractory Metastatic Colorectal Cancer." Journal of Clinical Pharmacology, vol. 65, no. 7, 2025, pp. 873-884, https://doi.org/10.1002/jcph.70001.